Detailed price information for Roche Holdings Ltd ADR (RHHBY) from The Globe and Mail including charting and trades.
The 5-year lung cancer survival rate has increased more than 25% over the past decade, highlighting the impact of increased ...
Researchers sought to determine whether brexucabtagene autoleucel would improve response rates among patients with relapsed or refractory CLL.
Unprecedented Phase 1 CML efficacy data with 64% MMR achievement by 24 weeks in a refractory patient population Encouraging safety and tolerability profile at all doses evaluated Company to host ...
Nurix Therapeutics recently announced the initiation of the pivotal Phase 2 DAYBreak trial of its BTK degrader candidate NX-5948 in relapsed or refractory chronic lymphocytic leukemia, alongside plans ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback